New progress in the treatment of polycythemia vera
10.12092/j.issn.1009-2501.2025.07.011
- VernacularTitle:真性红细胞增多症治疗新进展
- Author:
Yueming LI
1
;
Yongchao ZHANG
1
;
Fang CHEN
1
Author Information
1. 中国医科大学附属盛京医院血液研究室,沈阳 110004,辽宁
- Publication Type:Journal Article
- Keywords:
polycythemia vera;
ruxolitinib;
inter-feron
- From:
Chinese Journal of Clinical Pharmacology and Therapeutics
2025;30(7):961-967
- CountryChina
- Language:Chinese
-
Abstract:
Polycythemia vera(PV)is a type of BCR∷ABL1 negative myeloproliferative neoplasms(MPN),which is a chronic myeloid tumor caused by gene mutations in hematopoietic stem cells.PV has a certain risk of progressing to myelofibrosis or acute myeloid leukemia.At present,the goal of PV treatment is still to prevent thrombosis.With the deepening of PV research,it is possible to trans-form the lifelong treatment to prevent the progres-sion of the disease from alleviating the symptoms of patients.This article reviews the mechanism of traditional cytoreductive therapy drugs and the lat-est clinical trial results,as well as the early clinical trial data and their mechanism of action of new PV drugs and combination of drugs,in order to pro-vide help for researchers who pay attention to PV treatment.
